Formation Biologics Inc.

Formation Biologics Inc. is a biotechnology company focused on developing innovative biopharmaceuticals aimed at improving health outcomes, particularly in oncology and immunology through precision medicine. Formation Biologics Inc. was founded in 2011 in Austin, US, specializing in biotechnology solutions.

The company underwent a significant change when it was acquired by Bristol-Myers Squibb Company in September 2020. The founder's history and other details about the company's previous operations are not available. The most recent funding round occurred in August 2020, where the company raised CAD 1. 920 mn in a Series C round led by HBM Partners.

The total amount raised by the company stands at CAD 1. 920 mn across six deals, with the most recent deal date being August 24, 2020. Forbius specializes in developing innovative biotechnology solutions aimed at enhancing health outcomes. The company’s core product offerings include a range of biopharmaceuticals designed to address various medical conditions through therapeutic mechanisms.

These products are targeted at improving patient health in sectors such as oncology and immunology, focusing on precision medicine for tailored treatments. Forbius serves a diverse client base, including hospitals, specialty clinics, and research institutions across North America and Europe, reflecting its commitment to addressing unmet medical needs in these regions. The company's products are in various phases of development, with ongoing research aimed at expanding their therapeutic applications. Forbius generates revenue primarily through partnerships and direct sales of its biopharmaceutical products.

The company engages in B2B transactions, collaborating with healthcare providers and institutions to distribute its offerings. Revenue streams are supported by strategic partnerships with pharmaceutical companies, involving licensing agreements or co-development arrangements. Pricing plans are structured to reflect the value and efficacy of their flagship products in the market. As Forbius continues to expand its product line and market reach, revenue generation will be closely tied to the successful implementation of these strategic business relationships and the uptake of its therapies.

Since the acquisition by Bristol-Myers Squibb Company in September 2020, Formation Biologics Inc. has been focusing on integrating its innovative solutions within a larger portfolio. The recent funding will support the transition and development of new products as well as expansion into new markets. Specific future products and their release dates have not been disclosed, but the company is expected to leverage its capabilities in oncology and immunology.

The strategy aims to increase market presence in North America and Europe while further enhancing its product offerings.